A mathematical model to estimate global hepatitis B disease burden and vaccination impact.

By Susan T. Goldstein, F. Zhou, S. Hadler, B. Bell, E. Mast, H. Margolis. International Journal of Epidemiology, 2005

770 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. (2006, background): “Therefore, implementation of this strategy, which represents the most effective way of preventing chronic HBV infection and related end stage liver disease, is far from complete [107,108].”
Hepatocellular carcinoma: a review (2016, background): “The hepatocarcinogenicity of HBV can be significantly reduced with antiviral treatment for hepatitis B. Suppression of the virus can result in a significant 5-year reduction of the incidence of HCC from 13.7% (controls) to 3.7%, with the greatest reduction occurring in cirrhotic patients.10 The use ”
Epidemiological serosurvey of hepatitis B in China--declining HBV prevalence due to hepatitis B vaccination. (2009, neutral): “5 million future HBV related deaths have been prevented [21].”
Vaccine instability in the cold chain: mechanisms, analysis and formulation strategies. (2014, neutral): “million people chronically infected [157].”